Oncology

Psoriasis may increase the risk of cancer incidence and cancer-related mortality in affected individuals.

Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Top news of the day from across the health care landscape.

In addition to Jennifer Garner, actresses Julia Louis-Dreyfus and Christina Applegate are advocates for breast cancer, both being survivors of the disease.

Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.

Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.

Top news of the day from across the health care landscape.

After participating in a sleep-education program, 41% of participants who survived cancer had their insomnia successfully treated.

Top news of the week from Specialty Pharmacy Times.

Glenmark Pharmaceuticals has received FDA approval for abiraterone acetate tablets USP, 250 mg, a generic of Janssen's Zytiga tablets, 250 mg.1

Study suggests that blocking a signaling pathway that includes the inflammatory factor CXCL10-CXCR3 may prevent brain metastasis.

The full-day meeting will feature recognized experts sharing the latest clinical data in oncology, while exploring best practices and management strategies.

Expanded access to direct-acting antiviral drugs are vital to achieve elimination targets set by the World Health Organization for hepatitis C virus infections.

This article is the third in a series on difficult to pronounce drug names.

Ramucirumab (Cyramza) in combination with erlotinib delayed disease progression in previously untreated patients with EGFR-mutated non-small cell lung cancer.

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.

The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.

Top news of the day from across the health care landscape.

Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.

Ivosidenib improved progression-free survival with a promising trend toward improved overall survival in patients with IDH1-mutated cholangiocarcinoma.

Apalutamide (Erleada) showed an overall survival benefit in patients with non-metastatic castration-resistant prostate cancer.

A session at the ESMO Congress 2019 highlighted potential prevention and treatment strategies for life-threatening immunotherapy toxicities in patients with cancer.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen, discussed the increasing value of precision medicine in oncology and what will be needed to facilitate the use of precision medicine as more agents become available.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, oncology professor at the University of Copenhagen explained the challenges in identifying and treating TRK fusion cancer in patients.

New data confirm high activity of larotrectinib in pediatric and adult patients with TRK fusion cancer.

With more novel therapies entering the market, costs are on the rise, however, new research suggests that the price tag may not reflect the drug’s clinical value.

At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, professor of oncology at the University of Copenhagen, discussed the newly-released clinical data highlighting new overall survival and progression-free survival results for larotrectinib (Vitrakvi, Bayer) in tropomyosin receptor kinase (TRK) fusion cancer.